. Author manuscript; available in PMC: 2021 Jan 1.

Published in final edited form as: Curr Opin HIV AIDS. 2020 Jan;15(1):49–55. doi: 10.1097/COH.0000000000000600

Table 1.

Anti-HIV-1 broadly neutralizing antibodies in clinical development

Products		Target Site	Study Enpoints being Evaluated	References and/or Clinicaltrials.gov registry numbers [NCT]
Single Antibodies	VRC01	CD4bs	Safety and PK in HIV− and HIV+ adults and exposed infants	[9, 10, 19, 20, 22, 25, 39]
			Antiviral activity during viremia and analytical treatment interruption	[NCT02716675, NCT02568215, NCT02256631]
			Efficacy to prevent sexual transmission	[NCT02716675, NCT02568215, NCT02256631]
	3BNC117	CD4bs	Safety and PK in HIV− and HIV+ adults	[8, 24, 32]
	3BNC117	CD4bs	Antiviral activity during viremia and analytical treatment interruption
	10–1074	V3 loop	Safety and PK in HIV− and HIV+ adults	[11]
	10–1074	V3 loop	Antiviral activity during viremia
	PGT121	V3 loop	Safety and PK in HIV− and HIV+ adults	[14]
	PGT121	V3 loop	Antiviral activity during viremia
	PDGM-1400	V2 loop	Safety and PK in HIV− and HIV+ adults	[NCT03205917]
	PDGM-1400	V2 loop	Antiviral activity during viremia
	VRC01-LS	CD4bs	Safety and PK in HIV− and HIV+ adults and exposed infants	[12, 15]
	VRC01-LS	CD4bs	Antiviral activity during viremia	[NCT02256631]
	VRC07–523LS	CD4bs	Safety and PK in HIV− and HIV+ adults and exposed infants	[13, 15]
	VRC07–523LS	CD4bs	Antiviral activity during viremia	[NCT02256631]
	3BNC117-LS	CD4bs	Safety and PK in HIV− and HIV+ adults	[NCT03254277]
	10–1074-LS	V3 loop	Safety and PK in HIV− and HIV+ adults	[NCT03554408]
	10E8VLS	MPER	Safety and PK in HIV− adults	[NCT03565315]
	N6LS	CD4bs	Safety and PK in HIV− adults	[NCT03538626]
Antibody combinations	3BNC117 & 10–1074	CD4bs, V3 loop	Safety and PK in HIV− and HIV+ adults	[21, 23, 26]
	3BNC117 & 10–1074	CD4bs, V3 loop	Antiviral activity during viremia and analytical treatment interruption	[NCT03526848, NCT03571204]
	PGT121 & PGDM1400	V3 loop, V2 loop	Safety and PK in HIV− and HIV+ adults	[NCT03205917]
	PGT121 & PGDM1400	V3 loop, V2 loop	Antiviral activity during viremia	[NCT03205917]
	3BNC117-LS & 10–1074-LS	CDbs, V3 loop	Safety and PK in HIV− and HIV+ adults	[NCT03554408]
	VRC07–523LS & 10E8VLS	CD4bs, MPER	Safety and PK in HIV− adults	[NCT03565315]
	VRC01-LS & 10–1074	CD4bs, V3 loop	Safety, PK in HIV+ children	[NCT03707977]
	VRC01-LS & 10–1074	CD4bs, V3 loop	Antiviral activity during analytical treatment interruption	[NCT03707977]
	VRC01 & 10–1074	CD4bs, V3 loop	Antiviral activity during sequentiall ART interruption periods	[NCT03831945]
	VRC07–523LS & 10–1074	CD4bs, V3 loop	Safety and PK in HIV− adults	[NCT03928821]
	VRC07–523LS & PGT121	CD4bs, V3 loop	Safety, PK in HIV− adults	[NCT03721510]
	VRC07–523LS & PGT121 & PGDM1400	CD4bs, V3 loop, V2 loop	Safety, PK in HIV− and HIV+ adults	[NCT03721510, NCT03205917, NCT03928821]
	VRC07–523LS & PGT121 & PGDM1400	CD4bs, V3 loop, V2 loop	Antiviral activity during viremia and analytical treatment interruption	[NCT03721510, NCT03205917, NCT03928821]
Multi-specific antibodies	SAR441236	CD4bs, V2 loop, MPER	Safety, PK in HIV+ adults	[NCT03705169]
	SAR441236	CD4bs, V2 loop, MPER	Antiviral activity during viremia	[NCT03705169]
	10e8.4/iMAb	CD4, MPER	Safety, PK in HIV− and HIV+ adults	[NCT03875209]
	10e8.4/iMAb	CD4, MPER	Antiviral activity during viremia	[NCT03875209]
Antibody gene transfer	AAV1-PG9	V2 loop	Safety, PK in HIV− adults	[29]
Antibody gene transfer	AAV8-VRC07	CD4bs	Safety, PK in HIV+ adults	[NCT03374202]